Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial
Key Takeaways
- Retatrutide has no FDA approval, no labeled storage instructions, and no manufacturer beyond-use date for reconstituted forms
- Peptide stability literature for structurally similar GLP-1 analogues supports a roughly 28-42 day refrigerated window once reconstituted, depending on preparation
- Freeze-thaw cycles, temperature excursions, agitation, and light exposure all reduce shelf life
- Reconstitution and storage decisions belong to a state-licensed pharmacy operating under USP 797, not to individual users
- FormBlends does not sell or supply retatrutide. This article describes principles, not preparation steps
Direct answer
There is no labeled answer. Retatrutide is investigational and not FDA-approved, so there is no manufacturer-published expiry for a reconstituted form. Peptide stability research for similar GLP-1 family molecules suggests reconstituted shelf life in the range of 28-42 days at 2-8 degrees Celsius when prepared correctly with bacteriostatic water in a sterile environment. This is a research-context inference. Real beyond-use dating for any specific preparation is a compounding pharmacy determination under USP 797 standards.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Why this question has no labeled answer
- How peptide stability is actually measured
- Refrigerated stability of GLP-1 family peptides
- The vial-life vs dose-count distinction
- Conditions that shorten shelf life
- Where USP 797 fits
- What the phase 2 trial actually did
- Contrary view: are stability claims overcautious?
- Decision framework
- FAQ
- Sources
Why this question has no labeled answer
FDA-approved injectable peptides come with explicit storage instructions. Wegovy carries a 28-day in-use period at room temperature after first use, with refrigeration before that. Ozempic carries a 56-day in-use period. Mounjaro carries a 21-day in-use period. These numbers come from manufacturer stability studies submitted in the regulatory filing and validated by FDA review.
Retatrutide has no FDA approval. There is no labeled in-use period, no labeled storage range, and no FDA-reviewed stability dossier in the public domain. What exists publicly is journal-published phase 2 and phase 3 protocol information, and general peptide stability literature for related molecules.
Asking "how long does 10 mg retatrutide last" is therefore asking a question that does not have a regulatory answer. The closest substitute is what compounding pharmacies infer when they prepare similar peptides.
How peptide stability is actually measured
Pharmaceutical stability studies look at three categories of change:
- Chemical degradation. Hydrolysis at peptide bonds, oxidation of methionine residues, deamidation of asparagine and glutamine. Measured by mass spectrometry or HPLC. Drives loss of potency.
- Physical degradation. Aggregation, fibrillation, precipitation, adsorption to container walls. Measured by visual inspection, dynamic light scattering, and analytical centrifugation. Drives both loss of potency and immunogenicity risk.
- Microbiological contamination. Bacterial or fungal growth, particularly in multi-dose preparations. Controlled by sterile preparation and preservatives like benzyl alcohol.
A "shelf life" number rolls all three into a single conservative date past which the preparation is no longer presumed safe or potent. For an unapproved peptide, no one has run that consolidated study at scale.
Refrigerated stability of GLP-1 family peptides
Published stability data exists for related molecules and gives the closest available benchmark.
| Compound | Form | Approximate refrigerated stability | Source |
|---|---|---|---|
| Semaglutide (Ozempic, label) | Solution in pen | 56 days in use after first puncture | FDA label |
| Tirzepatide (Mounjaro, label) | Solution in pen | 21 days in use after first puncture | FDA label |
| Compounded semaglutide | Reconstituted from lyophilized | 28-42 days typical pharmacy BUD | 503A pharmacy USP 797 practice |
| GLP-1 family research peptides | Reconstituted with bacteriostatic water | 28-30 days commonly cited in peptide stability literature | Research methods sections |
By analogy, reconstituted retatrutide is unlikely to be markedly different in its refrigerated stability profile from these molecules. The structural class is similar, the preservative chemistry is identical when bacteriostatic water is used, and the dominant degradation pathways apply.
By analogy is not by validation. Without a retatrutide-specific stability study, any number is an estimate.
The vial-life vs dose-count distinction
A 10 mg vial divides into a certain number of doses depending on the schedule. This is dose math, not stability math.
| Weekly dose | Doses from a 10 mg vial | Calendar duration |
|---|---|---|
| 1 mg | 10 | ~10 weeks |
| 2 mg | 5 | ~5 weeks |
| 4 mg | 2 plus partial | ~2-3 weeks |
| 8 mg | 1 plus partial | ~1-2 weeks |
| 12 mg | Less than one full dose | Not enough |
If the dose math exceeds the stability window, some of the vial will degrade before it is used. A patient at 1 mg weekly will run a 10 mg vial over 10 weeks, which is longer than the 28-42 day refrigerated window typically inferred. At 4 mg or 8 mg, the vial is consumed well within any plausible stability window.
Conditions that shorten shelf life
Several real-world conditions cut the inferred shelf life:
- Refrigerator temperature excursions above 8 degrees Celsius (door storage, frequent opening, transport in a warm car)
- Freezing followed by thawing, including accidental contact with the refrigerator's back wall
- Agitation, including dropping the vial or shaking instead of swirling
- Light exposure during storage in clear or translucent containers
- Microbial introduction through repeated needle entries with poor aseptic technique
- Use of non-bacteriostatic water (plain sterile water, tap water, saline) as the diluent
Each of these is a reason a state-licensed compounding pharmacy controls the entire preparation environment rather than relying on individual users to maintain conditions.
Where USP 797 fits
United States Pharmacopeia General Chapter 797 governs sterile preparation of injectable medications. It specifies environmental requirements (cleanroom classification, air quality, surface disinfection), personnel requirements (gowning, training, competency assessment), and beyond-use dating rules for compounded sterile preparations.
Under USP 797, beyond-use dating for a sterile compounded preparation is set by the preparation conditions and the published or studied stability of the active ingredient. For an unapproved peptide like retatrutide, a 503A pharmacy preparing it under research-supply contracts must rely on the best available stability inference and document its reasoning.
Beyond-use dating is not a patient calculation. It is a pharmacy determination tied to a specific preparation lot, container, and storage protocol.
What the phase 2 trial actually did
In Jastreboff et al., trial supply was manufactured, packaged, and shipped by Lilly's clinical operations. Investigators received pre-labeled vials with appropriate handling instructions. The trial's stability questions were answered by the sponsor's manufacturing and quality systems. Investigator sites did not reconstitute their own preparations.
This is the standard model for an investigational compound. The stability data the sponsor holds internally is not publicly available the way an FDA label would be. Phase 3 (TRIUMPH) supply continues to use the same manufacturing model.
Contrary view: are stability claims overcautious?
Some research practitioners argue that the 28-42 day refrigerated window is conservative. Two arguments support extension.
The benzyl-alcohol argument. Bacteriostatic water with 0.9% benzyl alcohol meaningfully suppresses bacterial growth. In studies of related peptides, microbial contamination is rarely the rate-limiting failure mode in a properly sealed multi-dose vial; chemical degradation usually is. Vials kept consistently at 2-8 degrees can sometimes show acceptable potency at 60-90 days.
The "no studied difference" argument. Without a head-to-head stability study showing retatrutide degrades faster than its close analogues, applying the most conservative analogue's beyond-use date is arbitrarily tight.
The counter to both arguments: when there is no specific stability data, the safety-conservative choice is the shorter window. Loss of potency may be silent (the injection works less well, the patient does not realize it). The downside of an over-cautious shelf life is wasted drug. The downside of an over-aggressive shelf life is undertreatment.
This is exactly the calculus that USP 797 places in the hands of pharmacists and compounders, not patients.
Decision framework
If you are a patient interested in retatrutide: there is no consumer-safe answer to "how long does my vial last" because there is no consumer-facing retatrutide product to begin with. Discuss with a licensed clinician.
If you are a clinician evaluating compounded peptides: beyond-use dating for any specific preparation should come from the preparing pharmacy under USP 797 standards. Generic 28-42 day windows are starting points, not endpoints.
If you are evaluating a vial's calendar life against a dose schedule: compare the vial-to-doses count against the inferred stability window. If the math says the vial will outlast the window, the latter doses will be of uncertain potency.
Discuss with a licensed clinician.
FAQ
How long does reconstituted retatrutide stay stable in the fridge? Roughly 28-42 days at 2-8 degrees Celsius when reconstituted with bacteriostatic water under sterile conditions, by inference from peptide stability literature. There is no labeled value because retatrutide is not FDA-approved.
How long does a 10 mg vial last? Depends on dose. Five weeks at 2 mg weekly, two-plus at 4 mg, one-plus at 8 mg. Whether the vial lasts within its stability window depends on the schedule.
Can reconstituted retatrutide be frozen? Freeze-thaw cycles damage peptide structure. Freezing the dissolved form is generally not recommended.
What is bacteriostatic water? Sterile water containing 0.9% benzyl alcohol as a preservative. Standard diluent for multi-dose peptide preparations.
Why does dissolved peptide degrade faster than powder? Hydrolysis pathways open up when water is present, and physical degradation pathways become available. Solid lyophilized peptide is more stable than the reconstituted form.
Did the phase 2 trial reconstitute retatrutide on site? No. Trial supply was prepared by Lilly's clinical operations. Investigators did not handle reconstitution.
Is retatrutide light-sensitive? Most therapeutic peptides are light-sensitive to some degree. Standard practice is opaque or amber containers and dark refrigerated storage.
Who should make storage decisions? A state-licensed compounding pharmacy operating under USP 797, in coordination with a clinician. Not the individual user.
Related guides
- How Long Is Retatrutide Stable Once Reconstituted? What Peptide Stability Principles Suggest
- How Long Is Retatrutide Stable After Reconstitution?
- How Long Does Retatrutide Last in the Fridge? Beyond-Use Date Logic
- TRIUMPH-2 Trial: Retatrutide Long-Term Weight Maintenance
- Is Retatrutide Safe for Long-Term Use?
- How Long Until Retatrutide Reduces Appetite?
- Tool: reconstitution calculator
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM. 2023.
- USP General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2023 revision.
- USP General Chapter 1191: Stability Considerations in Dispensing Practice.
- FDA Prescribing Information for Ozempic (semaglutide). Storage and beyond-use section.
- FDA Prescribing Information for Mounjaro (tirzepatide). Storage and beyond-use section.
- FDA Prescribing Information for Wegovy (semaglutide). Storage and beyond-use section.
- Manning MC et al. Stability of Protein Pharmaceuticals: An Update. Pharmaceutical Research. 2010.
- Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nature Reviews Drug Discovery. 2005.
- National Association of Boards of Pharmacy. Compounding Standards Resource Guide.
- ClinicalTrials.gov NCT05298254 (Retatrutide phase 2 dose-finding study).
- FDA Drug Approvals Database (no retatrutide approval as of May 2026).
Footer disclaimers
Platform Disclaimer. FormBlends does not sell, supply, prescribe, dispense, or reconstitute retatrutide. Retatrutide is an investigational compound under phase 3 study by Eli Lilly and Company. It is not FDA-approved. This article is educational and reflects published peptide-stability principles.
Compounded Medication Notice. Compounded sterile injectables are prepared by state-licensed 503A pharmacies under USP 797 standards. Beyond-use dating, storage instructions, and stability of any compounded preparation are pharmacy responsibilities. Patients should not reconstitute or alter sterile injectable preparations on their own.
Results Disclaimer. Stability windows referenced in this article are inferred from analogue peptide literature, not measured for retatrutide specifically. Real shelf life depends on preparation conditions, container, and storage. Reduced potency from a degraded preparation may go undetected.
Trademark Notice. Retatrutide is an investigational compound owned by Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly. FormBlends is not affiliated with, endorsed by, or sponsored by any company referenced.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →